IL154017A0 - Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors - Google Patents

Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors

Info

Publication number: IL154017A0
Authority: IL; Israel
Prior art keywords: pharmaceutical compositions; transfer protein; cholesteryl ester; protein inhibitors; ester transfer
Prior art date: 2000-08-03

Application number

IL15401701A

Other languages

English (en)

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-03

Filing date

2001-07-31

Publication date

2003-07-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22835821&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL154017(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-07-31 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-07-31 Publication of IL154017A0 publication Critical patent/IL154017A0/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Hematology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)

IL15401701A 2000-08-03 2001-07-31 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors IL154017A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US22327900P	2000-08-03	2000-08-03
PCT/IB2001/001391 WO2002011710A2 (en)	2000-08-03	2001-07-31	Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors

Publications (1)

Publication Number	Publication Date
IL154017A0 true IL154017A0 (en)	2003-07-31

Family

ID=22835821

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL15401701A IL154017A0 (en)	2000-08-03	2001-07-31	Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors

Country Status (39)

Country	Link
US (4)	US7115279B2 (is)
EP (2)	EP1305007B1 (is)
JP (2)	JP2004505911A (is)
KR (1)	KR100561572B1 (is)
CN (1)	CN1458840A (is)
AP (1)	AP2001002235A0 (is)
AR (1)	AR030570A1 (is)
AT (1)	ATE503462T1 (is)
AU (1)	AU2914202A (is)
BG (1)	BG107456A (is)
BR (1)	BR0112828A (is)
CA (1)	CA2417755A1 (is)
CR (1)	CR6883A (is)
CZ (1)	CZ2003224A3 (is)
DE (1)	DE60144332D1 (is)
DO (1)	DOP2001000224A (is)
DZ (1)	DZ3391A1 (is)
EA (1)	EA007013B1 (is)
EC (1)	ECSP034462A (is)
EE (1)	EE200300052A (is)
GT (1)	GT200100156A (is)
HN (1)	HN2001000175A (is)
HU (1)	HUP0300676A2 (is)
IL (1)	IL154017A0 (is)
IS (1)	IS6688A (is)
MA (1)	MA26935A1 (is)
MX (1)	MXPA03001035A (is)
NO (1)	NO20030506L (is)
NZ (1)	NZ523680A (is)
OA (1)	OA12350A (is)
PA (1)	PA8523901A1 (is)
PE (1)	PE20020271A1 (is)
PL (1)	PL365168A1 (is)
SK (1)	SK1032003A3 (is)
SV (1)	SV2002000581A (is)
TN (1)	TNSN01119A1 (is)
UY (1)	UY26864A1 (is)
WO (1)	WO2002011710A2 (is)
ZA (1)	ZA200300869B (is)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7115279B2 (en) *	2000-08-03	2006-10-03	Curatolo William J	Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
DE10063486A1 (de) *	2000-12-20	2002-07-04	Bayer Ag	Dichlorpyridylmethylamide
IL158765A0 (en) *	2001-06-21	2004-05-12	Pfizer Prod Inc	Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
EP1399190B1 (en) *	2001-06-22	2010-09-08	Bend Research, Inc.	Pharmaceutical compositions comprising low-solubility and acid-sensitive drugs and neutralized acidic polymers
CA2450957A1 (en) *	2001-06-22	2003-01-03	Pfizer Products Inc.	Pharmaceutical compositions of dispersions of drugs and neutral polymers
JP2004534811A (ja) *	2001-06-22	2004-11-18	ファイザー・プロダクツ・インク	ポリマーと薬剤の集合体を含む医薬組成物
WO2003000238A1 (en) *	2001-06-22	2003-01-03	Pfizer Products Inc.	Pharmaceutical compositions of adsorbates of amorphous drug
CA2448864C (en) *	2001-06-22	2008-04-22	Pfizer Products Inc.	Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
IL162870A0 (en)	2002-02-01	2005-11-20	Pfizer Prod Inc	Controlled release pharmaceutical dosage forms of a cholesteryl estertransfer protein inhibitor
PL371593A1 (en) *	2002-02-01	2005-06-27	Pfizer Products Inc.	Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
BR0307344A (pt)	2002-02-01	2004-12-14	Pfizer Prod Inc	Composições farmacêuticas de dispersões amorfas de fármacos e materiais formadores de microfase lipofìlica
PL373914A1 (en) *	2002-02-01	2005-09-19	Pfizer Products Inc.	Immediate release dosage forms containing solid drug dispersions
EP1469833B1 (en) *	2002-02-01	2021-05-19	Bend Research, Inc.	Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
AR038375A1 (es) *	2002-02-01	2005-01-12	Pfizer Prod Inc	Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
AU2003249474A1 (en) *	2002-08-12	2004-02-25	Pfizer Products Inc.	Pharmaceutical compositions of semi-ordered drugs and polymers
US7504508B2 (en)	2002-10-04	2009-03-17	Millennium Pharmaceuticals, Inc.	PGD2 receptor antagonists for the treatment of inflammatory diseases
KR20050055747A (ko)	2002-10-04	2005-06-13	밀레니엄 파머슈티컬스 인코퍼레이티드	염증 질환 치료용의 ｐｇｄ2 수용체 길항제
EP1578415B1 (en) *	2002-12-20	2008-09-10	Pfizer Products Inc.	Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
US20040132771A1 (en) *	2002-12-20	2004-07-08	Pfizer Inc	Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
KR20050088190A (ko) *	2002-12-20	2005-09-02	화이자 프로덕츠 인코포레이티드	콜레스테릴 에스터 전달 단백질 억제제 및 ｈｍｇ-ｃｏａ환원 효소 억제제를 포함하는 투약 형태
ATE534381T1 (de) *	2003-03-17	2011-12-15	Japan Tobacco Inc	Pharmazeutische cetp-inhibitor-zusammensetzungen
ZA200508159B (en) *	2003-03-17	2007-03-28	Japan Tobacco Inc	Pharmaceutical compositions of CETP inhibitors
US7276536B2 (en) *	2003-03-17	2007-10-02	Japan Tobacco Inc.	Method for increasing the bioavailability of the active form of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino) phenyl] 2-methylpropanethioate
TWI494102B (zh) *	2003-05-02	2015-08-01	Japan Tobacco Inc	包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
BRPI0413277A (pt) *	2003-08-04	2006-10-10	Pfizer Prod Inc	composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
CL2004001884A1 (es) *	2003-08-04	2005-06-03	Pfizer Prod Inc	Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
BRPI0413363A (pt) *	2003-08-04	2006-10-10	Pfizer Prod Inc	formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase
CN1886124A (zh) *	2003-09-26	2006-12-27	日本烟草产业株式会社	抑制残余脂蛋白产生的方法
WO2005033082A2 (en) *	2003-09-30	2005-04-14	Pfizer Products Inc.	Cetp inhibitors and metabolites thereof
US7749992B2 (en) *	2003-10-08	2010-07-06	Eli Lilly And Company	Compounds and methods for treating dislipidemia
SI1759702T1 (sl) *	2004-05-26	2009-06-30	Bayardo Arturo Jimenez	Postopek pripravljanja oftalmiäśne raztopine latanoprosta in tako proizvedena raztopina
US7700774B2 (en)	2004-12-20	2010-04-20	Dr. Reddy's Laboratories Ltd.	Heterocyclic compounds and their pharmaceutical compositions
US8604055B2 (en)	2004-12-31	2013-12-10	Dr. Reddy's Laboratories Ltd.	Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
CN103102303B (zh)	2004-12-31	2015-10-28	雷迪博士实验室有限公司	作为cetp抑制剂的苄胺衍生物
WO2006082500A1 (en) *	2005-02-03	2006-08-10	Pfizer Products Inc.	Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
RU2007135224A (ru)	2005-02-24	2009-03-27	Милленниум Фармасьютикалз, Инк. (Us)	Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
WO2007056205A2 (en) *	2005-11-04	2007-05-18	Eastman Chemical Company	Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
US8030359B2 (en) *	2006-02-09	2011-10-04	Merck Sharp & Dohme Corp.	Polymer formulations of CETP inhibitors
PE20081506A1 (es) *	2006-12-12	2008-12-09	Infinity Discovery Inc	Formulaciones de ansamicina
EP1997819A1 (de)	2007-05-25	2008-12-03	Boehringer Ingelheim Pharma GmbH & Co. KG	Verfahren zur Herstellung von Scopinestern
US8337835B2 (en) *	2009-04-10	2012-12-25	Washington University	Use of an endogenous ligand for peroxisome proliferator activated receptor alpha to treat liver disorders
SMT202000093T1 (it)	2009-06-16	2020-03-13	Pfizer	Forme di dosaggio di apixaban
WO2012110469A1 (en)	2011-02-17	2012-08-23	F. Hoffmann-La Roche Ag	A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion
MX2013010306A (es)	2011-03-08	2013-12-09	Zalicus Pharmaceuticals Ltd	Formulaciones de dispersion solida y metodos de uso de las mismas.
JP5964965B2 (ja)	2011-08-18	2016-08-03	ドクターレディズラボラトリーズリミテッド	コレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての置換複素環式アミン化合物
CN103958511A (zh)	2011-09-27	2014-07-30	雷迪博士实验室有限公司	作为胆固醇酯转移蛋白(CETP)抑制剂用于治疗动脉粥样硬化的5-苄基氨基甲基-6-氨基吡唑并[3,4-b]吡啶衍生物
WO2014076568A2 (en) *	2012-11-19	2014-05-22	Dr. Reddy's Laboratories Ltd.	Pharmaceutical compositions of cetp inhibitors

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3871866D1 (de)	1987-07-17	1992-07-16	Dow Corning	Haertbare zusammensetzung.
JP2528706B2 (ja)	1988-05-30	1996-08-28	ゼリア新薬工業株式会社	ジヒドロピリジン化合物の製剤組成物
US5093371A (en)	1990-07-02	1992-03-03	University Of Iowa Research Foundation	Naphthyl ketone inhibitors of cholesterol esterase and their use as hypolipidemic and hypocaloric agents
JP2527107B2 (ja)	1991-04-16	1996-08-21	日本新薬株式会社	固体分散体の製造方法
US5340591A (en) *	1992-01-24	1994-08-23	Fujisawa Pharmaceutical Co., Ltd.	Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
US5446207A (en)	1993-09-01	1995-08-29	Harbor Branch Oceanographic Institution, Inc.	Anti-dyslipidemic agents
US5474993A (en)	1994-06-14	1995-12-12	Sterling Winthrop, Inc.	Lactam inhibitors of cholesterol esterase
US5880095A (en)	1994-11-12	1999-03-09	Lg Chemical Ltd.	Cholesteryl ester transfer protein inhibitor peptides and prophylactic and therapeutic anti-arteriosclerosis agents
WO1996019239A1 (en) *	1994-12-21	1996-06-27	Yamanouchi Pharmaceutical Co., Ltd.	Solid composition with improved solubility and absorbability
TW487582B (en) *	1995-08-11	2002-05-21	Nissan Chemical Ind Ltd	Method for converting sparingly water-soluble medical substance to amorphous state
GB2305665A (en)	1995-09-26	1997-04-16	Merck & Co Inc	Selective ß3 agonists for the treatment of diabetes aand obesity
DE19610932A1 (de)	1996-03-20	1997-09-25	Bayer Ag	2-Aryl-substituierte Pyridine
EP0801060A1 (en)	1996-04-09	1997-10-15	Pfizer Inc.	Heterocyclic Beta-3 Adrenergenic Agonists
HRP970330B1 (en)	1996-07-08	2004-06-30	Bayer Ag	Cycloalkano pyridines
DE19627431A1 (de)	1996-07-08	1998-01-15	Bayer Ag	Heterocyclisch kondensierte Pyridine
AR008789A1 (es)	1996-07-31	2000-02-23	Bayer Corp	Piridinas y bifenilos substituidos
JP3290962B2 (ja) *	1997-02-12	2002-06-10	日本たばこ産業株式会社	Ｃｅｔｐ活性阻害剤
JP2894445B2 (ja)	1997-02-12	1999-05-24	日本たばこ産業株式会社	Ｃｅｔｐ活性阻害剤として有効な化合物
DE19709125A1 (de)	1997-03-06	1998-09-10	Bayer Ag	Substituierte Chinoline
JPH10287662A (ja)	1997-04-08	1998-10-27	Kitasato Inst:The	Ｆｏ−５６３７ａ物質及びｂ物質並びにそれらの製造法
DE69824901D1 (de)	1997-04-16	2004-08-05	Univ New Mexico Albuquerque	Cholesterin Esterase Inhibitoren
US5955475A (en) *	1997-06-30	1999-09-21	Endo Pharmaceuticals Inc.	Process for manufacturing paroxetine solid dispersions
PT901786E (pt)	1997-08-11	2007-08-07	Pfizer Prod Inc	Disperções farmacêuticas sólidas com biodisponibilidade melhorada
WO1999014204A1 (en)	1997-09-16	1999-03-25	G.D. Searle & Co.	Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity
DE19741051A1 (de)	1997-09-18	1999-03-25	Bayer Ag	Hetero-Tetrahydrochinoline
MA24643A1 (fr)	1997-09-18	1999-04-01	Bayer Ag	Tetrahydro-naphtalenes substitues et composes analogues
DE19741399A1 (de)	1997-09-19	1999-03-25	Bayer Ag	Tetrahydrochinoline
AU3285499A (en)	1998-02-13	1999-08-30	G.D. Searle & Co.	Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
JP3433417B2 (ja) *	1998-04-02	2003-08-04	トヨタ自動車株式会社	レーダ装置
WO1999063970A1 (en)	1998-06-11	1999-12-16	Pharmacia & Upjohn Company	Delavirdine tablet formulation
US6197786B1 (en)	1998-09-17	2001-03-06	Pfizer Inc	4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6140342A (en) *	1998-09-17	2000-10-31	Pfizer Inc.	Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6147090A (en) *	1998-09-17	2000-11-14	Pfizer Inc.	4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) *	1998-09-17	1999-09-06		1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147089A (en) *	1998-09-17	2000-11-14	Pfizer Inc.	Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
ATE361273T1 (de)	1998-09-25	2007-05-15	Monsanto Co	Polycyclische aryl und heteroaryl substituierte tertiäre heteroalkylamine, für die hemmung der aktivität des cholesteryl-ester-transfer-proteins
JP2002525350A (ja)	1998-09-25	2002-08-13	モンサントカンパニー	コレステロールエステル輸送タンパク質活性阻害に有効な置換されたｎ−脂肪族−ｎ−芳香族第三級ヘテロアルキルアミン
US6706283B1 (en) *	1999-02-10	2004-03-16	Pfizer Inc	Controlled release by extrusion of solid amorphous dispersions of drugs
DE60039379D1 (de)	1999-02-10	2008-08-21	Pfizer Prod Inc	Pharmazeutische feste Dispersionen
AU751849B2 (en)	1999-03-08	2002-08-29	Kitasato Institute, The	Substances WK-5344A and WK-5344B and process for producing the same
US6465011B2 (en)	1999-05-29	2002-10-15	Abbott Laboratories	Formulations comprising lipid-regulating agents
US20010018446A1 (en)	1999-09-23	2001-08-30	G.D. Searle & Co.	Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
CO5271716A1 (es)	1999-11-30	2003-04-30	Pfizer Prod Inc	Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
GEP20043334B (en) *	1999-12-23	2004-03-10	Pfizer Prod Inc	Hydrogel-Driven Drug Dosage Form
US20010028895A1 (en)	2000-02-04	2001-10-11	Bisgaier Charles L.	Methods of treating alzheimer's disease
US7115279B2 (en) *	2000-08-03	2006-10-03	Curatolo William J	Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
CA2450957A1 (en)	2001-06-22	2003-01-03	Pfizer Products Inc.	Pharmaceutical compositions of dispersions of drugs and neutral polymers
EP1399190B1 (en)	2001-06-22	2010-09-08	Bend Research, Inc.	Pharmaceutical compositions comprising low-solubility and acid-sensitive drugs and neutralized acidic polymers
JP2004534811A (ja)	2001-06-22	2004-11-18	ファイザー・プロダクツ・インク	ポリマーと薬剤の集合体を含む医薬組成物
EP1469833B1 (en)	2002-02-01	2021-05-19	Bend Research, Inc.	Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
AR038375A1 (es) *	2002-02-01	2005-01-12	Pfizer Prod Inc	Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
KR20050088190A (ko) *	2002-12-20	2005-09-02	화이자 프로덕츠 인코포레이티드	콜레스테릴 에스터 전달 단백질 억제제 및 ｈｍｇ-ｃｏａ환원 효소 억제제를 포함하는 투약 형태

2001
- 2001-07-30 US US09/918,127 patent/US7115279B2/en not_active Expired - Fee Related
- 2001-07-31 SV SV2001000581A patent/SV2002000581A/es not_active Application Discontinuation
- 2001-07-31 DE DE60144332T patent/DE60144332D1/de not_active Expired - Lifetime
- 2001-07-31 IL IL15401701A patent/IL154017A0/xx unknown
- 2001-07-31 NZ NZ523680A patent/NZ523680A/en unknown
- 2001-07-31 SK SK103-2003A patent/SK1032003A3/sk not_active Application Discontinuation
- 2001-07-31 EP EP01984472A patent/EP1305007B1/en not_active Expired - Lifetime
- 2001-07-31 EA EA200300073A patent/EA007013B1/ru not_active IP Right Cessation
- 2001-07-31 EE EEP200300052A patent/EE200300052A/xx unknown
- 2001-07-31 EP EP20100180614 patent/EP2258352B1/en not_active Expired - Lifetime
- 2001-07-31 AT AT01984472T patent/ATE503462T1/de not_active IP Right Cessation
- 2001-07-31 DZ DZ013391A patent/DZ3391A1/xx active
- 2001-07-31 BR BR0112828-0A patent/BR0112828A/pt not_active IP Right Cessation
- 2001-07-31 WO PCT/IB2001/001391 patent/WO2002011710A2/en not_active Ceased
- 2001-07-31 CZ CZ2003224A patent/CZ2003224A3/cs unknown
- 2001-07-31 CN CN01815834A patent/CN1458840A/zh active Pending
- 2001-07-31 PL PL01365168A patent/PL365168A1/xx unknown
- 2001-07-31 JP JP2002517047A patent/JP2004505911A/ja active Pending
- 2001-07-31 KR KR1020037001456A patent/KR100561572B1/ko not_active Expired - Fee Related
- 2001-07-31 CA CA002417755A patent/CA2417755A1/en not_active Abandoned
- 2001-07-31 AU AU2914202A patent/AU2914202A/xx not_active Withdrawn
- 2001-07-31 MX MXPA03001035A patent/MXPA03001035A/es active IP Right Grant
- 2001-07-31 OA OA1200300022A patent/OA12350A/en unknown
- 2001-07-31 HU HU0300676A patent/HUP0300676A2/hu unknown
- 2001-08-01 DO DO2001P000224A patent/DOP2001000224A/es unknown
- 2001-08-01 UY UY26864A patent/UY26864A1/es not_active Application Discontinuation
- 2001-08-01 GT GT200100156A patent/GT200100156A/es unknown
- 2001-08-02 TN TNTNSN01119A patent/TNSN01119A1/fr unknown
- 2001-08-02 PE PE2001000773A patent/PE20020271A1/es not_active Application Discontinuation
- 2001-08-02 AR ARP010103694A patent/AR030570A1/es unknown
- 2001-08-02 AP APAP/P/2001/002235A patent/AP2001002235A0/en unknown
- 2001-08-03 PA PA20018523901A patent/PA8523901A1/es unknown
- 2001-08-06 HN HN2001000175A patent/HN2001000175A/es unknown
2003
- 2003-01-13 BG BG107456A patent/BG107456A/bg unknown
- 2003-01-16 IS IS6688A patent/IS6688A/is unknown
- 2003-01-16 CR CR6883A patent/CR6883A/es not_active Application Discontinuation
- 2003-01-23 MA MA27010A patent/MA26935A1/fr unknown
- 2003-01-31 NO NO20030506A patent/NO20030506L/no not_active Application Discontinuation
- 2003-01-31 ZA ZA200300869A patent/ZA200300869B/en unknown
- 2003-02-03 EC EC2003004462A patent/ECSP034462A/es unknown
2006
- 2006-06-02 US US11/421,888 patent/US8048452B2/en not_active Expired - Fee Related
2007
- 2007-04-30 US US11/799,447 patent/US8197848B2/en not_active Expired - Fee Related
- 2007-08-09 JP JP2007208058A patent/JP2007314573A/ja active Pending
2012
- 2012-06-12 US US13/494,668 patent/US8389011B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
NO20030506D0 (no)	2003-01-31
ECSP034462A (es)	2003-03-31
JP2004505911A (ja)	2004-02-26
TNSN01119A1 (fr)	2005-11-10
CN1458840A (zh)	2003-11-26
US8389011B2 (en)	2013-03-05
UY26864A1 (es)	2002-02-28
AU2914202A (en)	2002-02-18
US20070282009A1 (en)	2007-12-06
EA200300073A1 (ru)	2003-08-28
JP2007314573A (ja)	2007-12-06
EP1305007A2 (en)	2003-05-02
PA8523901A1 (es)	2002-04-25
US20020103225A1 (en)	2002-08-01
HN2001000175A (es)	2001-10-08
US8048452B2 (en)	2011-11-01
CZ2003224A3 (cs)	2004-02-18
SV2002000581A (es)	2002-10-24
IS6688A (is)	2003-01-16
BR0112828A (pt)	2003-07-01
EP2258352B1 (en)	2015-05-13
AP2001002235A0 (en)	2001-09-30
SK1032003A3 (en)	2004-05-04
DZ3391A1 (fr)	2002-02-14
US20120277315A1 (en)	2012-11-01
WO2002011710A3 (en)	2002-05-02
NO20030506L (no)	2003-01-31
GT200100156A (es)	2002-04-23
MA26935A1 (fr)	2004-12-20
DOP2001000224A (es)	2002-06-15
PE20020271A1 (es)	2002-04-08
OA12350A (en)	2006-05-16
EP2258352A2 (en)	2010-12-08
US8197848B2 (en)	2012-06-12
AR030570A1 (es)	2003-08-27
NZ523680A (en)	2004-09-24
EA007013B1 (ru)	2006-06-30
BG107456A (bg)	2003-09-30
EP1305007B1 (en)	2011-03-30
EP2258352A3 (en)	2013-08-14
CR6883A (es)	2003-11-25
US20060211654A1 (en)	2006-09-21
ATE503462T1 (de)	2011-04-15
DE60144332D1 (de)	2011-05-12
MXPA03001035A (es)	2003-05-27
KR20030026995A (ko)	2003-04-03
KR100561572B1 (ko)	2006-03-16
WO2002011710A2 (en)	2002-02-14
EE200300052A (et)	2004-12-15
US7115279B2 (en)	2006-10-03
PL365168A1 (en)	2004-12-27
CA2417755A1 (en)	2002-02-14
ZA200300869B (en)	2004-04-16
HUP0300676A2 (hu)	2003-08-28

Publication	Publication Date	Title
AU2914202A (en)	2002-02-18	Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
IL158765A0 (en)	2004-05-12	Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
EP1315500A4 (en)	2006-05-31	PHARMACEUTICAL COMPOSITIONS FOR TOPICAL ADMINISTRATION OF CYCLOOXYGENASE-2 INHIBITORS
DK1105122T3 (da)	2005-08-08	Pharmaceutical compositions containing lipase inhibitors
HUP0500173A3 (en)	2009-03-30	Alpha-sulphonamido-acetamide derivatives as beta-amyloid inhibitors and pharmaceutical compositions containing them
HUP0401819A3 (en)	2009-06-29	Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
HUP0400641A3 (en)	2010-03-29	Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
HUP0300318A3 (en)	2004-11-29	Pyrazolobenzodiazepines as cdk2 inhibitors and pharmaceutical compositions containing them and their use
PL371416A1 (en)	2005-06-13	Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
HUP0302412A3 (en)	2007-02-28	Betha-carboline derivatives useful as inhibitors of phosphodiesterase and pharmaceutical compositions containing the same
IS6254A (is)	2002-01-29	Lyfjasamsetningar sem innihalda HMG afoxunarensímlata
IL151320A0 (en)	2003-04-10	Pharmaceutical compositions of glycogen phosphorylase inhibitors
HUP0202891A3 (en)	2003-11-28	Biphenyl derivatives used as nhe-3 inhibitors and pharmaceutical compositions containing them
HUP0203311A3 (en)	2004-06-28	New pharmaceutical compositions of prolonged effect
HUP0201846A3 (en)	2002-11-28	Amonobenzophenones as inhibitors of il-1betha and tnf-alpha and pharmaceutical compositions containing them
HUP0001632A3 (en)	2001-12-28	Pharmaceutical compositions comprising selective phosphodiestherase inhibitors
HUP0201911A3 (en)	2002-11-28	Aminobenzophenones as inhibitors of il-1betha and tnf-alpha and pharmaceutical compositions containing them
HUP0303184A3 (en)	2008-03-28	Substituted c-cyclohexylmethylamine derivatives and pharmaceutical compositions containing them
IL163959A (en)	2010-12-30	Derivatives of phenyl-sulfonylamino- benzoic acid and pharmaceutical compositions comprising them
AU1189201A (en)	2001-05-08	Therapeutic compositions including protein kinase c inhibitors
HUP0303731A3 (en)	2006-02-28	Sulfonylguanidines and their use for preparation of pharmaceutical compositions
HUP0202457A3 (en)	2003-03-28	Substituted cinnamic acid derivatives as fatty acid synthase inhibitors and pharmaceutical compositions containing them
HUP0301010A3 (en)	2005-03-29	Dual inhibitors of cholesteryl ester and wax ester synthesis for sebaceous gland disorders and pharmaceutical compositions containing them
HUP0004461A3 (en)	2004-04-28	Use of apolipoprotein b secretion/microsomal triglyceride transfer protein inhibitor for producing pharmaceutical composition and these pharmaceutical compositions
HUP0200311A3 (en)	2002-12-28	Use of aroyl- or arylalkanoylpyridazines for preparation of pharmaceutical compositions